Support for Your Decision to Discharge
a Patient in Acute Care.
ViroGates launches initial public offering and raises new capital for commercialization. Read more here
ViroGates ønsker børsnotering og rejser ny kapital til kommercialisering. Læs mere her
ViroGates is an international Medtech company headquartered in Denmark that was founded in 2001.
ViroGates´ product line called suPARnostic® is a commercially available test, that can measure the protein called suPAR in the blood.
More than 500 publications have followed, substantiating suPAR as one of the most promising prognostic biomarker tools for various areas of healthcare.
What does an elevated suPAR level in 12 different disease areas imply for the patients prognosis?
Meet us at SEMES Emergency Conference in Toledo, Spain and hear about suPARnostic®!
ViroGates publishes prospectus for its initial public offering in Copenhagen.
ViroGates intends to strengthen its capital structure to intensify the continued commercial roll-out of its products and strengthen its product development, clinical documentation and global patent coverage.
suPARnostic® is developed to measure the amount of suPAR protein (soluble urokinase Plasminogen Activator Receptor) in human blood.
It is the only CE-IVD certified product range applied for clinical determination of suPAR in human EDTA and heparin-plasma.
Read our latest news in our Press Room regarding our products, our company, suPAR abstracts and presentations, conferences and congresses where you can find us etc.
ViroGates publishes prospectus for its initial public offering in Copenhagen. ViroGates intends to strengthen its capital structure to intensify the continued...
Meet us at SEMES Emergency Conference in Toledo, Spain and hear about suPARnostic®!
We will keep you updated about the latest news on suPAR, abstracts, our products and our company…
